7 February 2011

(“Sareum” or the “Company”)

Research Update: Positive Leukaemia Model Study

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce positive results from its pre-clinical in-vivo efficacy studies into acute myeloid leukaemia (AML), the most common form of adult leukaemia.

A recent study for Sareum’s Aurora+FLT3 Kinase programme showed that the leukaemia regressed to such an extent that no detectable cancer could be found in any of the cases treated (ten in total) with a Sareum compound. By comparison, leukaemia increased five to fifteen fold in the study examples treated without Sareum’s compound.  At six weeks following treatment, no detectable cancer could be found in two of the ten examples dosed with the Sareum compound. In the remaining eight treated examples, the average time taken for the leukaemia to increase 5-fold was six weeks, compared to two weeks in the untreated cases.

Sareum’s CEO, Dr Tim Mitchell, commented: “The results of Sareum’s study compare very favourably with those from similar pre-clinical studies published for Aurora kinase inhibitors currently undergoing clinical trials. We look forward to presenting the data to potential licencees. 350,000 people a year are diagnosed with leukaemia and we are very pleased to be contributing to the search for a cure for this disease”.

Sareum Holdings plc


Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements/Bidhi Bhoma

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce

020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk